Foundayo

Latest three-month snapshot through 2026-08-05 · 1 wave. Use the controls above to change the window.

GLP-1 Medications · 1 wave · n=72 answers, pooled

By model

How often each model brings the brand up in recommendation answers.

Share of recommendations over time

Wave-by-wave share of recommendation answers that named this brand.

What they call it

Recurring descriptions in the models' own words, grouped by theme.

• once-daily oral glp-1 pill ×18

  “**Foundayo (orforglipron)** is Eli Lilly’s once-daily oral GLP-1 receptor agonist for weight management.”

• no fasting requirement ×9

  “* **The Ultimate Convenience (No Food/Water Restrictions):** This is Foundayo’s biggest selling point.”

• oral glp-1 medication ×9

  “Foundayo is the brand name for **orforglipron**, Eli Lilly's new oral GLP-1 pill approved for weight management.”

• no injections ×8

  “* **No Needles or Refrigeration:** For anyone with needle phobia, oral tablets are a massive relief.”

• newly approved ×7

  “These alternatives range from direct-to-consumer manufacturer discounts on tirzepatide itself, to newly approved weight-loss pills, older oral medications, and compounding options.”

• daily pill ×5

  “| **Foundayo (orforglipron)** — oral incretin medication | **$149–$299/month** through Lilly’s self-pay program, depending on dose | Closest new lower-cost alternative to GLP-1/GIP-style treatment; it’s a daily pill rather than Zepbound’s weekly injection.”

• fda-approved ×5

  “- It’s an FDA-approved **once-daily oral GLP-1** for chronic weight management.”

• common side effects ×4

  “probably worth considering—not an automatic yes. Foundayo (orforglipron) is a legitimate FDA-approved, once-daily oral GLP-1 medication for adults with obesity, or overweight plus a weight-related condition, alongside diet and activity changes. Its main advantage is convenience: ”

• cheapest legitimate fda-approved glp-1 ×3

  “- A new non-peptide oral GLP-1, orforglipron (brand name Foundayo), was FDA-approved April 1, 2026, and runs $25 per month with commercial insurance, $149 cash — the de facto answer for a cheap oral GLP-1 pill in 2026, without needing the SNAC absorption technology that locks gen”

• first non-peptide oral glp-1 ×3

  “- **Foundayo (orforglipron)** – A brand-new oral GLP-1 option: Eli Lilly's Foundayo (orforglipron), FDA-approved April 1, 2026, is the first non-peptide oral GLP-1 and runs $25 per month with commercial insurance, $149 cash.”

In their words

70 exact quoted mentions in this snapshot, grouped by coded tone. Recent quotes are deduplicated and mixed across models.

What they recommend

“Qualifying patients may be able to receive Wegovy, Zepbound Kwikpen, or Foundayo for $50/month”

“Qualifying patients may receive Wegovy, Zepbound, or Foundayo for $50/month through their Medicare Bridge partnership.”

“If you want to avoid needles, this is a daily oral pill. It is a "small-molecule" GLP-1, meaning you can take it at any time of day with no strict food or water restrictions, making it highly convenient.”

“**Foundayo (orforglipron) – *Cheapest Oral Option*:** Approved by the FDA as a daily weight-loss pill, Eli Lilly offers Foundayo through its **LillyDirect** self-pay program. Starter doses begin as low as **$149 per month**, with higher mai”

“Foundayo (orforglipron) — daily GLP-1 pill | **$149/month** starting dose; generally **$299/month** at higher doses with Lilly's refill program | FDA-approved in April 2026; a real GLP-1 option without injections. Likely the lowest-cost bra”

Where they hedge

“**Short answer: yes—if you qualify, want to avoid injections, and can tolerate/afford a daily GLP‑1 pill.** It is a legitimate FDA-approved prescription medication (orforglipron), not a supplement or compounded product. But it is not automa”

“Foundayo is worth considering if: You strongly prefer pills over injections... It may not be worth it if: You're already succeeding on an injectable like Zepbound (switching risks weight regain)”

“Foundayo is Eli Lilly's new once-daily oral GLP-1 pill for weight loss, and while it's already positioned as one of the more affordable branded GLP-1 options”

“Whether Foundayo is "worth it" depends on your weight-loss goals, budget, aversion to needles, and lifestyle preferences.”

“Whether **Foundayo** (orforglipron) is "worth it" depends on what you value most in a weight-loss treatment: the convenience of a pill, the flexibility of your daily schedule, the total amount of weight you want to lose, and your budget.”

The substitution map

Which competitors models suggest when shoppers ask for something cheaper.

Where this comes from

10 of 70 mentions appear alongside an identifiable web citation. Citation does not establish causation.

Where they send you

Stores and sites models name as places to buy this brand.

Method: fixed shopper questions asked repeatedly to Claude, OpenAI GPT and Gemini with web search on. Shares are the percentage of recommendation answers mentioning the brand. Quotes are AI outputs; full transcripts are kept as receipts.